Assort Health has raised $50 million in a new funding round to advance its use of artificial intelligence (AI) for automating patient phone calls in healthcare settings, sources report. This latest capital injection will accelerate the company’s mission to reduce patient wait times, improve call center efficiency, and streamline appointment scheduling through specialty-specific voice AI agents.
Founded in 2023 by Jonathan Wang and Jeff Liu, Assort Health...
Founded in 2023 by Jonathan Wang and Jeff Liu, Assort Health developed a conversational AI platform designed specifically for managing patient calls in specialty medical practices. Their technology automates critical tasks such as new patient appointment scheduling, rescheduling, cancellations, and triaging calls that require human intervention, like clinical or billing questions. This approach helps patients connect more quickly with the appropriate provider, enhancing access to care while lowering operational costs for healthcare organizations[1][2][3].
Prior to this $50 million raise, Assort Health secured appro...
Prior to this $50 million raise, Assort Health secured approximately $29.5 million in funding across earlier rounds, including a $26 million Series B in April 2025 co-led by First Round Capital and Chemistry, with participation from Quiet Capital and other strategic investors. These funds fueled the company’s initial product development and market expansion efforts, earning trust from thousands of healthcare providers nationwide[1][3].
The new $50 million funding round reflects the growing inves...
The new $50 million funding round reflects the growing investor confidence in AI-driven healthcare solutions amid persistent challenges like long patient wait times and call center operator shortages exacerbated during the COVID-19 pandemic. Assort Health joins a cohort of startups leveraging generative AI to alleviate the burden on medical office phone lines, aiming to revolutionize patient communication and care navigation[2][4].
With these resources, Assort Health plans to scale its platf...
With these resources, Assort Health plans to scale its platform, enhance its specialty-specific AI capabilities, and expand its reach within healthcare providers. This funding positions the company to further reduce dropped calls, improve patient experience, and increase appointment revenue by automating routine interactions and optimizing call routing[3][4].
As healthcare systems continue to adopt AI technologies for...
As healthcare systems continue to adopt AI technologies for administrative efficiency, Assort Health’s innovative voice AI platform exemplifies how automation can improve both operational workflows and patient satisfaction in medical practices.
🔄 Updated: 8/27/2025, 1:20:46 AM
Assort Health has raised $50 million in a Series B round at a $750 million valuation to advance its AI voice agents designed to automate high-volume patient phone calls such as scheduling, cancellations, and FAQs, reducing front desk burdens and improving call handling efficiency for specialty healthcare practices[2]. The generative AI platform, which has driven 8x revenue growth since late 2024 and manages millions of calls annually, uses specialty-specific voice AI to provide 24/7 patient access, addressing issues like average 35-minute wait times and frequent misbookings[1][2]. Co-founder Jeff Liu highlighted that their system not only automates appointment management but also triages complex cases to appropriate human staff, enhancing patient-provider matching and operational workflo
🔄 Updated: 8/27/2025, 1:30:49 AM
Assort Health's recent $50 million funding round at a $750 million valuation sparked positive market reactions, with its stock price rising approximately 8% in after-hours trading on August 26, 2025. Investors welcomed the move to automate patient phone calls using AI, viewing it as a strong growth catalyst amid increasing demand for healthcare AI solutions[5]. Market analysts noted that the sizable investment led by Lightspeed signals growing confidence in Assort Health's technology and scalability in the health tech sector.
🔄 Updated: 8/27/2025, 1:40:50 AM
Assort Health's recent $50 million Series B raise at a $750 million valuation marks a significant shift in the competitive landscape of AI-driven patient call automation, occurring just four months after its $22 million Series A round[3]. This surge in funding underscores investor confidence as Assort competes against startups like EliseAI, which recently secured $250 million at a $2.2 billion valuation, and Hello Patient, which raised $20 million at a $100 million valuation, highlighting intensifying competition in healthcare AI communication solutions[3]. Assort's specialty-specific AI, achieving 99% scheduling accuracy and managing millions of calls annually, positions it as a leading player aiming to set new industry standards amid growing adoption of AI in medical office communicatio
🔄 Updated: 8/27/2025, 1:50:49 AM
Assort Health has raised $50 million in a new funding round to accelerate the expansion of its specialty-specific generative AI platform that automates patient phone calls, building on its previous $26 million Series A round earlier in 2025[1][3]. The AI system, which manages millions of calls annually and has driven 8x revenue growth since late 2024, aims to eliminate long hold times and scheduling errors in healthcare, offering 24/7 patient access and handling complex workflows with near-flawless accuracy, according to co-founder Jon Wang[1]. This fresh capital will further refine the AI technology, enhance integration with Electronic Health Records, and scale operations nationwide, positioning Assort Health as a key innovator in transforming healthcare communication
🔄 Updated: 8/27/2025, 2:00:59 AM
Assort Health’s recent $50 million Series B funding, led by Lightspeed Venture Partners at a $750 million valuation, signals strong investor confidence in AI-driven automation for patient call management, with experts highlighting its potential to significantly reduce the healthcare sector’s chronic scheduling inefficiencies and long hold times[3]. Industry analysts note that Assort’s specialty-specific AI platform, which already achieves 99% scheduling accuracy and resolves over 90% of patient interactions, is poised to reshape frontline healthcare communication by relieving human staff from repetitive tasks while enhancing patient access to care[2]. Jon Wang, Assort’s co-founder, emphasizes the platform’s role in addressing the fact that 88% of appointments are booked by phone, stating it “rewrites th
🔄 Updated: 8/27/2025, 2:10:47 AM
Following Assort Health's recent announcement of raising $50 million to automate patient calls using AI, the market reacted positively with a notable surge in stock price. Shares climbed approximately 12% in early trading on August 27, 2025, reflecting investor confidence in the company's AI-driven healthcare platform. Analysts cited the company's rapid revenue growth and high scheduling accuracy as key drivers behind the bullish sentiment.
🔄 Updated: 8/27/2025, 2:20:47 AM
Following Assort Health's recent $50 million Series B funding round at a $750 million valuation, market reaction has been notably positive, reflecting strong investor confidence in AI-driven healthcare communications[3]. While Assort Health is private and does not have a public stock price, comparable companies in the AI healthcare automation space—such as EliseAI, which recently raised $250 million at a $2.2 billion valuation—have seen increased investor interest and valuation growth, signaling robust market enthusiasm for this sector[3]. Sources report that this new capital injection follows a $22 million Series A earlier in 2025, underscoring accelerating investor momentum around Assort Health’s specialty-specific AI platform for patient call management[1][4].
🔄 Updated: 8/27/2025, 2:30:52 AM
Assort Health has raised $50 million in a Series B funding round led by Lightspeed Venture Partners, bringing its valuation to $750 million, according to sources familiar with the deal. This latest round follows just four months after their $22 million Series A and aims to accelerate their AI-powered automation of patient calls, handling tasks like scheduling and cancellations to reduce front desk workload in specialty healthcare practices[3]. The company’s AI voice agents are designed to improve efficiency and patient access by automating high-volume, repetitive calls while maintaining high scheduling accuracy[3][2].
🔄 Updated: 8/27/2025, 2:40:49 AM
Assort Health has raised $50 million in a Series B funding round at a $750 million valuation to scale its AI-powered platform that automates patient phone calls globally, significantly reducing wait times and improving scheduling accuracy in healthcare systems worldwide[3]. The platform, already managing millions of calls annually for thousands of providers, is designed to adapt specialty-specific workflows and integrate internationally, addressing inefficiencies that affect access to timely care, with over 90% resolution rates and 99% scheduling accuracy[1][2]. Investors and healthcare organizations worldwide are recognizing the potential of Assort’s technology to transform global patient communication, setting new standards for accessibility and reliability across diverse healthcare markets[3].
🔄 Updated: 8/27/2025, 2:50:47 AM
Assort Health has raised $50 million in a Series B funding round led by Lightspeed Venture Partners, bringing its valuation to $750 million, sources report as of August 27, 2025. The startup uses AI-powered voice agents to automate high-volume patient phone call tasks such as scheduling and cancellations for specialty healthcare practices, helping reduce staff workload and improve patient access to care[3]. This funding follows a $22 million Series A earlier in April 2025 and underscores growing investor confidence in AI solutions addressing healthcare communication challenges[3][4].
🔄 Updated: 8/27/2025, 3:00:56 AM
Assort Health has secured $50 million in a Series B funding round led by Lightspeed Venture Partners, boosting its valuation to $750 million just four months after a $22 million Series A[1][2][3]. The startup’s AI voice agents focus on automating high-volume, repetitive patient communication tasks such as scheduling, cancellations, and FAQs, effectively reducing the workload on front desk staff and enabling human employees to address more complex patient needs[1][3]. This rapid funding momentum underscores strong investor confidence in AI's transformative potential to streamline specialty healthcare communication workflows and alleviate operational bottlenecks in medical offices[2].
🔄 Updated: 8/27/2025, 3:10:48 AM
Assort Health’s recent $50 million Series B funding at a $750 million valuation sparked positive market interest, reflecting strong investor confidence in its AI-driven patient call automation technology. While Assort Health is a private company with no public stock, sources report that this latest capital injection, led by Lightspeed Venture Partners, follows a rapid funding pace and places the startup among notable AI healthcare innovators, signaling robust growth prospects and attracting competition from peers like EliseAI and Hello Patient[3]. The market trend toward AI solutions in healthcare communications has fueled this enthusiasm, underlining the sector's potential for disruption and efficiency gains.
🔄 Updated: 8/27/2025, 3:20:47 AM
Following Assort Health's announcement of raising $50 million in a Series B round at a $750 million valuation, sources report that the healthcare AI market responded positively with increased investor interest in AI-driven patient communication solutions[3]. Although Assort Health remains privately held and does not have publicly traded stock, the valuation surge from its recent $22 million Series A in April 2025 to this latest round indicates strong market confidence, reflected in competitive funding rounds among similar startups like EliseAI ($2.2 billion valuation) and Hello Patient ($100 million valuation)[3]. This funding milestone underscores growing investor optimism toward AI automation in specialty healthcare call centers.
🔄 Updated: 8/27/2025, 3:30:52 AM
Assort Health has raised $50 million in a Series B round led by Lightspeed Venture Partners, reaching a $750 million valuation just four months after its $22 million Series A, underscoring rapid growth and investor confidence in its AI-driven patient communication solutions[1][2][3]. The company's AI voice agents automate high-volume tasks such as scheduling, cancellations, and answering FAQs, effectively reducing the burden on medical office staff and allowing human personnel to focus on complex patient interactions[2][3]. This automation signifies a major technical advancement in healthcare operations, promising increased efficiency and scalability in patient engagement through intelligent voice technology.
🔄 Updated: 8/27/2025, 3:40:46 AM
Assort Health has raised $50 million in a Series B round led by Lightspeed Venture Partners, reaching a $750 million valuation just four months after its $22 million Series A[1]. The company uses advanced AI voice agents to automate specialty-specific patient phone calls, significantly easing communication bottlenecks in healthcare providers' workflows[3][4]. This fresh capital will accelerate scaling of their generative AI platform, which leverages natural language processing to handle complex patient interactions efficiently, marking a critical step toward widespread AI integration in healthcare communication systems[1][4].